An open clinical study of tebipenem pivoxil in children with acute otitis media and acute upper respiratory tract infection (phase II)

Keisuke Sunakawa, Noboru Yamanaka, Satoshi Iwata, Kyoichi Totsuka, Yoshio Aizawa, Seiji Hori, Naoichi Iwai, Kimiko Ubukata

Research output: Contribution to journalArticle

Abstract

We conducted an open clinical study of an oral carbapenem, tebipenem pivoxil (TBPM-PI), in pediatric patients with acute otitis media and acute upper respiratory tract infection to assess efficacy, safety, and drug compliance. We also assessed dosage and administration at 4 mg/kg bid and 6 mg/kg bid set based on confirmatory study results for dosage and administration in adult patients. 1. Clinical effect: Response at the end of administration or at discontinuation was 100% (12/12) in the 4 mg/kg bid group and 100% (10/ 10) in the 6 mg/kg bid group. 2. Bacteriological effect: Bacteriological effectiveness was shown for all 7 strains of causative microorganisms isolated-3 strains in the 4 mg/ kg bid group and 4 strains in the 6 mg/kg bid group - at the end of administration or at discontinuation. 3. Safety: The incidence of adverse drug reaction (subjective symptoms and objective findings) were 16.7% (2/12) in the 4 mg/kg bid group and 36.4% (4/11) in the 6 mg/kg bid group. Common adverse drug reactions included diarrhea and loose stool. In adverse drug reactions related to laboratory tests one case in the 6 mg/kg bid group showed increased AST and ALT. No cases withdrew from the study due to adverse events. 4. Pharmacokinetics and PK-PD: Pharmacokinetics were examined in 22 cases for whom plasma TBPM concentration could be measured, and increase in Cmax and AUC0-24h were noted as dosage increased. PK-PD parameters in 7 strains in 6 cases analyzed for PK-PD showed 13 to 4,810 for AUCf/MIC, 9 to 3,145 for Cmaxf/MIC, and 11 to 100% for T>MIC. 5. Drug compliance: The proportion of cases judged to be "very easy to take" or "easy to take" was 95.7%. In conclusion, clinically recommended dosage and administration of TBPM-PI in the treatment of pediatric acute otitis media and acute upper respiratory tract infection was 4 mg/kg bid.

Original languageEnglish
Pages (from-to)115-124
Number of pages10
JournalJapanese Journal of Chemotherapy
Volume57
Issue numberSUPPL. 1
Publication statusPublished - 2009 Mar
Externally publishedYes

Fingerprint

Otitis Media
Drug-Related Side Effects and Adverse Reactions
Respiratory Tract Infections
Pharmacokinetics
Pediatrics
Safety
Carbapenems
Pharmaceutical Preparations
Diarrhea
Incidence
tebipenem
Clinical Studies

Keywords

  • Acute otitis media
  • Child
  • Oral carbapenem
  • Tebipenem pivoxil
  • Upper respiratory tract infection

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Sunakawa, K., Yamanaka, N., Iwata, S., Totsuka, K., Aizawa, Y., Hori, S., ... Ubukata, K. (2009). An open clinical study of tebipenem pivoxil in children with acute otitis media and acute upper respiratory tract infection (phase II). Japanese Journal of Chemotherapy, 57(SUPPL. 1), 115-124.

An open clinical study of tebipenem pivoxil in children with acute otitis media and acute upper respiratory tract infection (phase II). / Sunakawa, Keisuke; Yamanaka, Noboru; Iwata, Satoshi; Totsuka, Kyoichi; Aizawa, Yoshio; Hori, Seiji; Iwai, Naoichi; Ubukata, Kimiko.

In: Japanese Journal of Chemotherapy, Vol. 57, No. SUPPL. 1, 03.2009, p. 115-124.

Research output: Contribution to journalArticle

Sunakawa, K, Yamanaka, N, Iwata, S, Totsuka, K, Aizawa, Y, Hori, S, Iwai, N & Ubukata, K 2009, 'An open clinical study of tebipenem pivoxil in children with acute otitis media and acute upper respiratory tract infection (phase II)', Japanese Journal of Chemotherapy, vol. 57, no. SUPPL. 1, pp. 115-124.
Sunakawa, Keisuke ; Yamanaka, Noboru ; Iwata, Satoshi ; Totsuka, Kyoichi ; Aizawa, Yoshio ; Hori, Seiji ; Iwai, Naoichi ; Ubukata, Kimiko. / An open clinical study of tebipenem pivoxil in children with acute otitis media and acute upper respiratory tract infection (phase II). In: Japanese Journal of Chemotherapy. 2009 ; Vol. 57, No. SUPPL. 1. pp. 115-124.
@article{86c48e07e657471db597d58117dddeea,
title = "An open clinical study of tebipenem pivoxil in children with acute otitis media and acute upper respiratory tract infection (phase II)",
abstract = "We conducted an open clinical study of an oral carbapenem, tebipenem pivoxil (TBPM-PI), in pediatric patients with acute otitis media and acute upper respiratory tract infection to assess efficacy, safety, and drug compliance. We also assessed dosage and administration at 4 mg/kg bid and 6 mg/kg bid set based on confirmatory study results for dosage and administration in adult patients. 1. Clinical effect: Response at the end of administration or at discontinuation was 100{\%} (12/12) in the 4 mg/kg bid group and 100{\%} (10/ 10) in the 6 mg/kg bid group. 2. Bacteriological effect: Bacteriological effectiveness was shown for all 7 strains of causative microorganisms isolated-3 strains in the 4 mg/ kg bid group and 4 strains in the 6 mg/kg bid group - at the end of administration or at discontinuation. 3. Safety: The incidence of adverse drug reaction (subjective symptoms and objective findings) were 16.7{\%} (2/12) in the 4 mg/kg bid group and 36.4{\%} (4/11) in the 6 mg/kg bid group. Common adverse drug reactions included diarrhea and loose stool. In adverse drug reactions related to laboratory tests one case in the 6 mg/kg bid group showed increased AST and ALT. No cases withdrew from the study due to adverse events. 4. Pharmacokinetics and PK-PD: Pharmacokinetics were examined in 22 cases for whom plasma TBPM concentration could be measured, and increase in Cmax and AUC0-24h were noted as dosage increased. PK-PD parameters in 7 strains in 6 cases analyzed for PK-PD showed 13 to 4,810 for AUCf/MIC, 9 to 3,145 for Cmaxf/MIC, and 11 to 100{\%} for T>MIC. 5. Drug compliance: The proportion of cases judged to be {"}very easy to take{"} or {"}easy to take{"} was 95.7{\%}. In conclusion, clinically recommended dosage and administration of TBPM-PI in the treatment of pediatric acute otitis media and acute upper respiratory tract infection was 4 mg/kg bid.",
keywords = "Acute otitis media, Child, Oral carbapenem, Tebipenem pivoxil, Upper respiratory tract infection",
author = "Keisuke Sunakawa and Noboru Yamanaka and Satoshi Iwata and Kyoichi Totsuka and Yoshio Aizawa and Seiji Hori and Naoichi Iwai and Kimiko Ubukata",
year = "2009",
month = "3",
language = "English",
volume = "57",
pages = "115--124",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "SUPPL. 1",

}

TY - JOUR

T1 - An open clinical study of tebipenem pivoxil in children with acute otitis media and acute upper respiratory tract infection (phase II)

AU - Sunakawa, Keisuke

AU - Yamanaka, Noboru

AU - Iwata, Satoshi

AU - Totsuka, Kyoichi

AU - Aizawa, Yoshio

AU - Hori, Seiji

AU - Iwai, Naoichi

AU - Ubukata, Kimiko

PY - 2009/3

Y1 - 2009/3

N2 - We conducted an open clinical study of an oral carbapenem, tebipenem pivoxil (TBPM-PI), in pediatric patients with acute otitis media and acute upper respiratory tract infection to assess efficacy, safety, and drug compliance. We also assessed dosage and administration at 4 mg/kg bid and 6 mg/kg bid set based on confirmatory study results for dosage and administration in adult patients. 1. Clinical effect: Response at the end of administration or at discontinuation was 100% (12/12) in the 4 mg/kg bid group and 100% (10/ 10) in the 6 mg/kg bid group. 2. Bacteriological effect: Bacteriological effectiveness was shown for all 7 strains of causative microorganisms isolated-3 strains in the 4 mg/ kg bid group and 4 strains in the 6 mg/kg bid group - at the end of administration or at discontinuation. 3. Safety: The incidence of adverse drug reaction (subjective symptoms and objective findings) were 16.7% (2/12) in the 4 mg/kg bid group and 36.4% (4/11) in the 6 mg/kg bid group. Common adverse drug reactions included diarrhea and loose stool. In adverse drug reactions related to laboratory tests one case in the 6 mg/kg bid group showed increased AST and ALT. No cases withdrew from the study due to adverse events. 4. Pharmacokinetics and PK-PD: Pharmacokinetics were examined in 22 cases for whom plasma TBPM concentration could be measured, and increase in Cmax and AUC0-24h were noted as dosage increased. PK-PD parameters in 7 strains in 6 cases analyzed for PK-PD showed 13 to 4,810 for AUCf/MIC, 9 to 3,145 for Cmaxf/MIC, and 11 to 100% for T>MIC. 5. Drug compliance: The proportion of cases judged to be "very easy to take" or "easy to take" was 95.7%. In conclusion, clinically recommended dosage and administration of TBPM-PI in the treatment of pediatric acute otitis media and acute upper respiratory tract infection was 4 mg/kg bid.

AB - We conducted an open clinical study of an oral carbapenem, tebipenem pivoxil (TBPM-PI), in pediatric patients with acute otitis media and acute upper respiratory tract infection to assess efficacy, safety, and drug compliance. We also assessed dosage and administration at 4 mg/kg bid and 6 mg/kg bid set based on confirmatory study results for dosage and administration in adult patients. 1. Clinical effect: Response at the end of administration or at discontinuation was 100% (12/12) in the 4 mg/kg bid group and 100% (10/ 10) in the 6 mg/kg bid group. 2. Bacteriological effect: Bacteriological effectiveness was shown for all 7 strains of causative microorganisms isolated-3 strains in the 4 mg/ kg bid group and 4 strains in the 6 mg/kg bid group - at the end of administration or at discontinuation. 3. Safety: The incidence of adverse drug reaction (subjective symptoms and objective findings) were 16.7% (2/12) in the 4 mg/kg bid group and 36.4% (4/11) in the 6 mg/kg bid group. Common adverse drug reactions included diarrhea and loose stool. In adverse drug reactions related to laboratory tests one case in the 6 mg/kg bid group showed increased AST and ALT. No cases withdrew from the study due to adverse events. 4. Pharmacokinetics and PK-PD: Pharmacokinetics were examined in 22 cases for whom plasma TBPM concentration could be measured, and increase in Cmax and AUC0-24h were noted as dosage increased. PK-PD parameters in 7 strains in 6 cases analyzed for PK-PD showed 13 to 4,810 for AUCf/MIC, 9 to 3,145 for Cmaxf/MIC, and 11 to 100% for T>MIC. 5. Drug compliance: The proportion of cases judged to be "very easy to take" or "easy to take" was 95.7%. In conclusion, clinically recommended dosage and administration of TBPM-PI in the treatment of pediatric acute otitis media and acute upper respiratory tract infection was 4 mg/kg bid.

KW - Acute otitis media

KW - Child

KW - Oral carbapenem

KW - Tebipenem pivoxil

KW - Upper respiratory tract infection

UR - http://www.scopus.com/inward/record.url?scp=65249178336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249178336&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:65249178336

VL - 57

SP - 115

EP - 124

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - SUPPL. 1

ER -